MX2022004741A - Uso de compuestos de imidazopirimidina o imidazotriazina para prevencion, alivio, o tratamiento de trastornos cognitivos, o para mejorar la funcion cognitiva. - Google Patents

Uso de compuestos de imidazopirimidina o imidazotriazina para prevencion, alivio, o tratamiento de trastornos cognitivos, o para mejorar la funcion cognitiva.

Info

Publication number
MX2022004741A
MX2022004741A MX2022004741A MX2022004741A MX2022004741A MX 2022004741 A MX2022004741 A MX 2022004741A MX 2022004741 A MX2022004741 A MX 2022004741A MX 2022004741 A MX2022004741 A MX 2022004741A MX 2022004741 A MX2022004741 A MX 2022004741A
Authority
MX
Mexico
Prior art keywords
imidazopyrimidine
alleviation
prevention
treatment
cognitive function
Prior art date
Application number
MX2022004741A
Other languages
English (en)
Inventor
Jin Yong Chung
Chan Mi Joung
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2022004741A publication Critical patent/MX2022004741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona a un uso de compuestos de imidazopirimidina o imidazotriazina de la Fórmula Química 1, o sales, solvatos, o hidratos farmacéuticamente aceptables de los mismos, para prevenir, aliviar o tratar trastorno cognitivo o para mejorar la función cognitiva.
MX2022004741A 2019-10-21 2020-10-21 Uso de compuestos de imidazopirimidina o imidazotriazina para prevencion, alivio, o tratamiento de trastornos cognitivos, o para mejorar la funcion cognitiva. MX2022004741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190130384 2019-10-21
PCT/KR2020/014399 WO2021080312A1 (ko) 2019-10-21 2020-10-21 인지 장애의 예방, 경감 또는 치료, 또는 인지 기능 향상을 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도

Publications (1)

Publication Number Publication Date
MX2022004741A true MX2022004741A (es) 2022-05-16

Family

ID=75619896

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022004741A MX2022004741A (es) 2019-10-21 2020-10-21 Uso de compuestos de imidazopirimidina o imidazotriazina para prevencion, alivio, o tratamiento de trastornos cognitivos, o para mejorar la funcion cognitiva.

Country Status (13)

Country Link
US (1) US20220370461A1 (es)
EP (1) EP4049662A4 (es)
JP (1) JP2022553323A (es)
KR (1) KR20220087474A (es)
CN (1) CN114929230A (es)
AU (1) AU2020370958A1 (es)
BR (1) BR112022007491A2 (es)
CA (1) CA3155209A1 (es)
CL (1) CL2022001015A1 (es)
IL (1) IL292276A (es)
MX (1) MX2022004741A (es)
WO (1) WO2021080312A1 (es)
ZA (1) ZA202204136B (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723332B2 (en) * 2000-05-26 2004-04-20 Neurogen Corporation Oxomidazopyridine-carboxamides
WO2007023242A1 (en) * 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
US7563797B2 (en) * 2006-08-28 2009-07-21 Forest Laboratories Holding Limited Substituted imidazo(1,2-A)pyrimidines and imidazo(1,2-A) pyridines as cannabinoid receptor ligands
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
WO2012125732A1 (en) * 2011-03-15 2012-09-20 Vanderbilt University Substituted imadazapyrinidin-5(6h)-ones as allosteric modulators of mglur5 receptors
SG11201508201VA (en) * 2013-05-02 2015-11-27 Pfizer Imidazo-triazine derivatives as pde10 inhibitors
JP2016132660A (ja) * 2015-01-22 2016-07-25 大日本住友製薬株式会社 新規イミダゾピリミジンおよびその医薬用途
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物

Also Published As

Publication number Publication date
EP4049662A4 (en) 2023-11-01
US20220370461A1 (en) 2022-11-24
BR112022007491A2 (pt) 2022-07-12
JP2022553323A (ja) 2022-12-22
CL2022001015A1 (es) 2023-12-15
AU2020370958A1 (en) 2022-06-09
WO2021080312A1 (ko) 2021-04-29
CN114929230A (zh) 2022-08-19
KR20220087474A (ko) 2022-06-24
EP4049662A1 (en) 2022-08-31
IL292276A (en) 2022-06-01
CA3155209A1 (en) 2021-04-29
ZA202204136B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023010411A (es) Inhibidores de erbb/btk.
MX2023005099A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2021006695A (es) Moduladores de trex1.
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
PH12021550554A1 (en) N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors
MX2023009060A (es) Antagonistas de gpr84 y usos de estos.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
PH12017500638A1 (en) Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis
MX2023009059A (es) Antagonistas de gpr84 y usos de estos.
MX2022004741A (es) Uso de compuestos de imidazopirimidina o imidazotriazina para prevencion, alivio, o tratamiento de trastornos cognitivos, o para mejorar la funcion cognitiva.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
HK1106494A1 (en) Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MX2019006941A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.
IL288234A (en) Compounds for the treatment of neuromuscular disorders
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
MX2022002684A (es) Metodo de tratamiento o prevencion de la enfermedad renal cronica.
PH12018501100A1 (en) Phenylimidazole compound